The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief

--(BUSINESS WIRE)-- (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the Foot & Ankle Society's Winter Scientific Seminar to be held in .

'Podiatrists see patients every day who are suffering from chronic pain including nerve pain,' says , Senior Vice President and General Manager, Consumer. 'Quell is a new 100% drug free technology that addresses a variety of chronic pain conditions. Patients can wear it 24/7 so they can continue to get therapy while they are sleeping. We see podiatrists as key partners in helping more people with chronic pain to try Quell.'

About Quell

Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. It is available for purchase at QuellRelief.com, selected retailers and healthcare professionals.

About NeuroMetrix

NeuroMetrix is an innovative healthcare company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com :http://www.businesswire.com/news/home/20160128005971/en/

, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source:

News Provided by Acquire Media

NeuroMetrix Inc. issued this content on 28 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 28 January 2016 16:18:16 UTC

Original Document: http://investor.neurometrix.com/releasedetail.cfm?releaseid=952250